Priyank Desai, MD
Pulmonary Disease · Rocky Mount, NCNPI 1316148794
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $160,462 of the $198,709 with a category attached, or 80.8%. 27 manufacturers reported payments, led by GSK at 50.8% of the total. Reporting peaked in 2021 at $49,235 and has fallen 90.8% since, to $4,543 in 2025. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 570 payments — averaging $348.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$101K
- Boehringer Ingelheim$32K
- AstraZeneca$31K
- Mylan Specialty L.p.$19K
- Sunovion Pharmaceuticals Inc.$8K
- Viiv Healthcare Company$4K
- plus $4K from 21 others
Across 46 payments — averaging $3425.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$116K
- Chiesi USA, Inc.$41K
What the payments were for
- Consulting fees$11,4206%
- Speaking & faculty fees$160,46281%
- Travel & lodging$15,4968%
- Food & beverage$11,2136%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 205 | $100,925 |
| Boehringer Ingelheim | 88 | $31,514 |
| AstraZeneca | 82 | $31,041 |
| Mylan Specialty L.p. | 40 | $19,025 |
| Sunovion Pharmaceuticals Inc. | 38 | $7,908 |
| Viiv Healthcare Company | 4 | $4,341 |
| Mallinckrodt Hospital Products Inc. | 22 | $1,677 |
| Olympus Corporation Of The Americas | 13 | $1,318 |
| Amgen | 34 | $262 |
| Sanofi | 6 | $109 |
| Genentech USA, Inc. | 6 | $104 |
| Insmed, Inc. | 3 | $58 |
| Grifols USA, LLC | 3 | $58 |
| ANI Pharmaceuticals, Inc. | 2 | $53 |
| Novartis | 2 | $43 |
| Medtronic | 2 | $40 |
| United Therapeutics Corporation | 8 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| CSL Behring | 2 | $31 |
| Shionogi Inc | 1 | $20 |
| Breathe Technologies, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Inogen, Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $15 |
| Viatris Specialty LLC | 1 | $13 |
| Merck | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$85,108
- BREZTRI$25,652
- Yupelri$18,592
- OFEV$9,655
- LONHALA MAGNAIR$7,454
- ANORO$5,090
- ANORO ELLIPTA$3,600
- FASENRA$2,836
- BREZTRI AEROSPHERE$2,628
- SYMBICORT$2,520
- TEZSPIRE$1,884
- AIRSUPRA$1,403
- ACTHAR$1,245
- SINGLE USE SUCTION VALVE (Sterile)$1,045
- FARXIGA$481
- BEVESPI AEROSPHERE$275
How this compares
$198,709 in reported general payments places this provider in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 929 | $677,264 |
| OfevNintedanib Esylate | 30 | $495,453 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 416 | $300,266 |
| TezspireTezepelumab-Ekko | 36 | $158,462 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $117,025 |
| Breo ElliptaFluticasone/Vilanterol | 186 | $85,001 |
| NucalaMepolizumab | 17 | $72,913 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 86 | $47,338 |
| Spiriva RespimatTiotropium Bromide | 21 | $16,405 |
| EliquisApixaban | 24 | $16,296 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $8,812 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 344 | $8,420 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $7,529 |
| Epinephrine | 20 | $5,147 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $5,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta | $100,925 | $882,5171,218 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $31,514 | $520,67069 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $31,041 | $471,352484 claims |
| Grifols USA, LLCProlastin C | $58 | $117,02513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Rocky Mount
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
- Jill OharWinston Salem$226K
- Raed SuleimanGastonia$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.